| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 31.01.
| Shares of BioSante and Cell Therapeutics on the Upswing as Biotech Sector Rallies / Five Star Equities Provides Stock Research on BioSante Pharmaceuticals & Cell Therapeutics | | 87 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 01/31/12 -- Biotechnology stocks have been on a tear this month, gaining an impressive 11 percent. Reuters recently released an article arguing health-care costs are...
Mehr lesen zu:
Shares of BioSante and Cell Therapeutics on the Upswing as Biotech Sector Rallies / Five Star Equities Provides Stock Research on BioSante Pharmaceuticals & Cell Therapeutics | |
| 31.01.
| Hasn't Cell Therapeutics Ever Heard of All-Nighters? | | 7 | Motley Fool |
| 30.01.
| Hot Stock: Cell Therapeutics, Shares Drop 16.6% | | 11 | SmarTrend |
| 30.01.
| Cell Therapeutics Plummeting on NDA Withdrawl | | 2 | Benzinga.com |
| 30.01.
| Cell Therapeutics (CTIC) Withdrawals Pixuvri NDA, Will Resubmit in FY12 | | 4 | StreetInsider.com |
| 30.01.
| More Drama From Cell Therapeutics | | 14 | Seeking Alpha |
| 30.01.
| Cell Therapeutics Pulls Cancer Drug After CEO Boasted About Approval Chances | | 4 | The Street |
| 30.01.
| Cell Therapeutics withdraws Pixuvri NDA | | 1 | Pharma Bus Review |
| 30.01.
| Cell Therapeutics Voluntarily Withdraws Its NDA For Pixuvri | | 75 | AFX News |
| WASHINGTON (dpa-AFX) - Cell Therapeutics Inc (CTIC) Monday stated that it
has voluntarily withdrawn its New Drug Application, or NDA, for Pixuvri for the
treatment of relapsed or refractory...
Mehr lesen zu:
Cell Therapeutics Voluntarily Withdraws Its NDA For Pixuvri | |
| 30.01.
| Cell Therapeutics Withdraws New Drug Application for Pixuvri' and Plans to Resubmit in 2012 | | 69 | PR Newswire |
| SEATTLE, Jan. 30, 2012 /PRNewswire/ --Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has voluntarily withdrawn its New Drug Application ("NDA") for Pixuvri (pixantrone)...
Mehr lesen zu:
Cell Therapeutics Withdraws New Drug Application for Pixuvri' and Plans to Resubmit in 2012 | |
| 24.01.
| Possible Bearish Inside Day Candle Pattern Detected for Cell Therapeutics | | 5 | SmarTrend |
| 24.01.
| Buy, Sell, or Hold: Cell Therapeutics | | 16 | Motley Fool |
| 23.01.
| Cell Therapeutics Up 9.9%, Shares Break Through Resistance | | 14 | SmarTrend |
| 20.01.
| Cell Therapeutics (CTIC) to Get EMA Opinion on Pixuvri MAA in Mid-February FY12 | | 15 | StreetInsider.com |
| 20.01.
| Cell Therapeutics Expects CHMP's Opinion On Pixuvri By Mid February | | 110 | AFX News |
| WASHINGTON (dpa-AFX) - Cell Therapeutics Inc (CTIC) Friday announced that
the Committee for Medicinal Products for Human Use, or the CHMP, of the European
Medicines Agency may issue an opinion...
Mehr lesen zu:
Cell Therapeutics Expects CHMP's Opinion On Pixuvri By Mid February | |
| 20.01.
| Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri' in Mid-February | | 112 | PR Newswire |
| SEATTLE, Jan. 20, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that, following discussions with the European Medicines Agency's ("EMA")...
Mehr lesen zu:
Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri' in Mid-February | |
| 17.01.
| Dendreon and Cell Therapeutics - Starting Strong in 2012 / The Paragon Report Provides Equity Research on Dendreon Corporation & Cell Therapeutics | | 67 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 01/17/12 -- Biotechnology stocks have been on fire of late. The iShares Biotechnology index is up more than 12 percent over the last month as investors brace for big...
Mehr lesen zu:
Dendreon and Cell Therapeutics - Starting Strong in 2012 / The Paragon Report Provides Equity Research on Dendreon Corporation & Cell Therapeutics | |
| 15.01.
| Lowest Return on Equity in the Biotechnology Industry Detected in Shares of Cell Therapeutics | | - | SmarTrend |
| 14.01.
| Shares of Cell Therapeutics Rank the Lowest in Terms of Return on Equity in the Biotechnology Industry | | 2 | SmarTrend |
| 05.01.
| Battered Down Shares of Cell Therapeutics and BioSante Look to Rebound in 2012 / The Bedford Report Provides Equity Research on Cell Therapeutics & BioSante Pharmaceuticals | | 272 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 01/05/12 -- The always volatile biotechnology industry had its share of winners and losers last year. Overall, the biotech space was up more than 9 percent in 2011,...
Mehr lesen zu:
Battered Down Shares of Cell Therapeutics and BioSante Look to Rebound in 2012 / The Bedford Report Provides Equity Research on Cell Therapeutics & BioSante Pharmaceuticals | |
